We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.49 | -1.62% | 29.84 | 29.83 | 29.84 | 30.15 | 29.81 | 29.92 | 3,350,109 | 20:54:44 |
From Apr 2019 to Apr 2024
By Olivia Bugault
Roche Holding AG said late Tuesday that the U.S. Food and Drug Administration has extended its review of risdiplam, an experimental drug for the treatment of spinal muscular atrophy.
The Swiss pharmaceutical giant said the FDA decision is now expected by the end of August, compared with May 24 previously.
"The extension is a result of the recent submission of additional data by Roche, including data from the pivotal Sunfish Part 2 study," it said, adding that the data "could help ensure access to risdiplam for a broad range of people living with the condition, if approved."
Roche has also submitted filing applications in seven other countries for risdiplam, including in Brazil, Chile and South Korea, while a submission in China is imminent, it said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
April 08, 2020 01:30 ET (05:30 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
